Lilly bags eye-catching retinal disease gene therapy from MeiraGTx in $475M deal

Eli Lily Expands into Ophthalmology with Acquisition of Adverum Biotechnologies

With 2 FDA nods for Eylea HD, Regeneron is 'no longer fighting Vabysmo with both hands tied behind its back,' analyst says